top of page


Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Vice President for Research and Development at TAU. He is the co-founder and the managing director of SPARK Tel Aviv, Center for Translational Medicine. From 2016–2020 he was the chair of the TAU Cancer Biology Research Center.


Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference for drug discovery in immune cells. In addition, his lab was the first to show systemic, cell- specific delivery of modified mRNA expressing therapeutic proteins that has enormous implications in cancer, inflammation and infectious diseases. Prof. Peer is one of the pioneers in the use of molecular medicines  (gene silencing, gene expression and gene editing) for therapeutics and disease management.


Prof. Peer is a scientific advisory board member in more than 15 companies and on the scientific advisory board of 20 journals. He is a past President of the Israeli Chapter of the Controlled Release Society, and a past member of the Board of the Israel Young Academy of Science. His technologies were licensed to Companies like Roche, BioNtech SE, ART Biosciences, RiboX Therapeutics, and NeoVac Ltd.

bottom of page